SCHEDULE: Ventyx Bioscience: 13G Filing Shows 0% Ownership

Affinity Asset Advisors, LLC and Michael Cho report holding 0% of Ventyx Bioscience's common stock as of March 31, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for Ventyx Bioscience, Inc.
• Affinity Asset Advisors, LLC, a Delaware limited liability company, and Michael Cho, a U.S. citizen, are the reporting persons.
• As of March 31, 2026, both Affinity Asset Advisors, LLC and Michael Cho collectively beneficially own 0 shares of Ventyx Bioscience's common stock.
• This represents approximately 0.0% of the class of securities outstanding.
• The reporting persons have no sole or shared power to vote or direct the vote, nor sole or shared power to dispose or direct the disposition of any shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as having a very low sentiment score due to the complete absence of reported ownership, which provides no positive indication of investment interest or confidence in the company.

Negatives

• The reporting persons hold zero shares, indicating no investment or stake in the company as of the reporting date.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors or other entities that acquire beneficial ownership of more than 5% of a company's voting stock. The absence of any reported ownership in this filing by Affinity Asset Advisors, LLC and Michael Cho is unusual for entities typically associated with significant investment positions.

Stakeholder Impact

• Shareholders: The filing provides no indication of current or past significant investment by Affinity Asset Advisors, LLC or Michael Cho, which could influence market perception or investor interest.

Key Dates

Keywords

Ventyx Bioscience, Schedule 13G, Affinity Asset Advisors, Michael Cho, SEC Filing, Ownership, Beneficial Ownership, Common Stock